Form 8-K
8-K — Estrella Immunopharma, Inc.
Accession: 0001213900-26-113912
Filed: 2026-10-29
Period: 2026-10-25
CIK: 0001844417
SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Other Events
Item: Financial Statements and Exhibits
Documents
8-K — ea0310209-8k_estrella.htm (Primary)
EX-10.1 — EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND CYNTHIA PUSSINEN (ea031020901ex10-1.htm)
EX-10.2 — AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND CHENG LIU, PH.D (ea031020901ex10-2.htm)
EX-10.3 — AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND JIANDONG (PETER) XU (ea031020901ex10-3.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — CURRENT REPORT
8-K (Primary)
Filename: ea0310209-8k_estrella.htm · Sequence: 1
false
0001844417
0001844417
2026-10-25
2026-10-25
0001844417
ESLA:CommonStockParValue0.0001PerShareMember
2026-10-25
2026-10-25
0001844417
ESLA:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember
2026-10-25
2026-10-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 25, 2026
ESTRELLA IMMUNOPHARMA, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-40608
86-1314502
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
5858 Horton Street, Suite 370
Emeryville, California
94608
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (510) 318-9098
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
ESLA
The Nasdaq Stock Market LLC
Warrants, each warrant exercisable for one share of Common Stock, each at an exercise price of $11.50 per share
ESLAW
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On October 25, 2026, the Board
of Directors (the “Board”) of Estrella Immunopharma, Inc. (the “Company”) appointed Cynthia Pussinen, age 57,
as Chief Executive Officer of the Company and as a Class I director and Chairperson of the Board, in each case effective October 25, 2026.
Ms. Pussinen is not expected to be named to any committee of the Board. Effective October 25, 2026, Cheng Liu, Ph.D., ceased to serve
as Chief Executive Officer and was appointed Chief Scientific Officer; Dr. Liu continues to serve as President and as a director of the
Company.
From March 2026 to October
2026, Ms. Pussinen served as Managing Director, Biotech Investments, of Sorbie Bornholm Ltd., an investment firm focused on micro- and
small-capitalization public companies, and since 2023 she has provided strategic and operational consulting services to life sciences
companies and investors. From August 2023 to August 2024, she was Chief Executive Officer and a director of Sernova Corp., a clinical-stage
cell therapy company, and from January 2021 to November 2022 she was Chief Technical Officer of Spark Therapeutics, Inc., a gene therapy
company and a member of the Roche Group, where she was responsible for technical development, manufacturing and operations.
Other than as described below,
there are no arrangements or understandings between Ms. Pussinen and any other person pursuant to which she was selected as an officer
or director. Ms. Pussinen has no family relationship with any director or executive officer of the Company, and there are no transactions
involving Ms. Pussinen that would require disclosure under Item 404(a) of Regulation S-K.
In connection with her appointment,
the Company entered into an Employment Agreement with Ms. Pussinen, dated as of October 25, 2026 (the “Employment Agreement”),
which was approved by the Compensation Committee of the Board (the “Compensation Committee”) and the Board and pursuant to
which the Company agreed to appoint Ms. Pussinen as Chairperson of the Board and to nominate her for election as a director during her
employment. The Employment Agreement provides for an annual base salary of $250,000, which will increase automatically to $400,000, $450,000
and $525,000 when cumulative qualifying funding received by the Company after October 25, 2026 first exceeds $35.0 million, $55.0 million
and $75.0 million, respectively, and an annual cash bonus with a target of 60% of base salary for 2026 and, thereafter, a target of 55%
to 70% of base salary as set by the Compensation Committee. If Ms. Pussinen’s employment is terminated by the Company without cause
or by her for good reason (each as defined in the Employment Agreement), she will be entitled, subject to her execution of a release of
claims, to 12 months of base salary continuation, any earned but unpaid bonus for the prior year, a prorated target bonus for the year
of termination and up to 12 months of employer-paid COBRA premiums; if such a termination occurs within 90 days before or 12 months after
a change in control, she will instead receive 12 months of base salary in a lump sum, any earned but unpaid bonus for the prior year,
her full target bonus for the year of termination, up to 12 months of employer-paid COBRA premiums and full acceleration of her unvested
equity awards.
1
The Employment Agreement also
provides for, and the Compensation Committee and the Board approved, the grant to Ms. Pussinen under the Company’s 2023 Omnibus
Incentive Plan of an option to purchase 1,000,000 shares of the Company’s common stock, to be granted on the second business day
following the filing of this Current Report with an exercise price equal to the closing price of the common stock on The Nasdaq Stock
Market on the grant date. The option will have a ten-year term and will vest as to 25% of the shares on October 25, 2027 and as to the
remainder in 36 equal monthly installments thereafter, subject to Ms. Pussinen’s continued service and to the acceleration described
above. The Employment Agreement also provides for the indemnification of Ms. Pussinen to the fullest extent permitted by Delaware law
and requires the Company to enter into its standard form of indemnification agreement with her. In addition, the Compensation Committee
and the Board approved the deferral of Ms. Pussinen’s base salary on the same terms as the deferral of the base salaries of Dr.
Liu and Mr. Xu described below.
The foregoing description
of the Employment Agreement is qualified in its entirety by reference to the Employment Agreement, which is filed as Exhibit 10.1 hereto
and incorporated herein by reference.
Also on October 25, 2026,
the Company entered into Amendment No. 1 to its Employment Agreement dated as of November 1, 2024 with Dr. Liu and Amendment No. 1 to
its Employment Agreement dated as of September 29, 2023 with Jiandong (Peter) Xu, the Company’s Chief Financial Officer (together,
the “Amendments”), each of which was approved by the Compensation Committee and the Board. The Amendments reflect Dr. Liu’s
position as President and Chief Scientific Officer, including his consent to the change in his position described above, and conform the
base salary, annual cash bonus, benefits and severance and change in control terms of Dr. Liu and Mr. Xu to those provided to Ms. Pussinen
under the Employment Agreement as described above, with the automatic base salary increases measured by reference to cumulative qualifying
funding received after October 25, 2026. The Amendments do not provide for any new equity awards. The Company continues to defer payment
of the base salaries of Dr. Liu and Mr. Xu, as adjusted by the Amendments, without interest, pending the completion of additional financing.
The foregoing description
of the Amendments is qualified in its entirety by reference to the Amendments, which are filed as Exhibits 10.2 and 10.3 hereto and incorporated
herein by reference.
Item
8.01 Other Events.
On October 25, 2026, the Board
adopted resolutions providing that the Board will not exercise its authority under Article V, Section A of the Company’s Second
Amended and Restated Certificate of Incorporation to leave any class of directors unoccupied and will fill any class that would otherwise
have no members, so that directors stand for election at each annual meeting of stockholders. Following Ms. Pussinen’s appointment
as a Class I director, each of the three classes of directors has at least one member. The Board also adopted a resolution proposing,
and declaring advisable, an amendment to Article V, Section A that would eliminate that authority and provide that the three classes of
directors be as nearly equal in number as possible, directed that the proposed amendment be submitted to stockholders for approval at
the Company’s 2027 annual meeting of stockholders, and resolved that, if the proposed amendment is not approved at that meeting,
the Board will submit it, or an amendment having substantially the same effect, for stockholder approval at each subsequent annual meeting
of stockholders until it is approved. The proposed amendment will be described in the Company’s proxy statement for the 2027 annual
meeting.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
10.1†
Employment Agreement, dated as of October 25, 2026, by and between Estrella Immunopharma, Inc. and Cynthia Pussinen.
10.2†
Amendment No. 1 to Employment Agreement, dated as of October 25, 2026, by and between Estrella Immunopharma, Inc. and Cheng Liu, Ph.D.
10.3†
Amendment No. 1 to Employment Agreement, dated as of October 25, 2026, by and between Estrella Immunopharma, Inc. and Jiandong (Peter) Xu.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
† Indicates a management contract or compensatory plan or arrangement.
2
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
ESTRELLA IMMUNOPHARMA, INC.
Date: October 29, 2026
By:
/s/ Peter Xu
Name:
Peter Xu
Title:
Chief Financial Officer
3
EX-10.1 — EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND CYNTHIA PUSSINEN
EX-10.1
Filename: ea031020901ex10-1.htm · Sequence: 2
Exhibit 10.1
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (the “Agreement”),
dated as of October 25, 2026, is made by and between Estrella Immunopharma, Inc. a Delaware corporation (the “Company”), and
Cynthia Pussinen (“Executive”). This Agreement shall govern the employment relationship between Executive and the Company
from and after the Effective Date (as defined below).
WHEREAS, the Company desires to employ Executive
as its Chief Executive Officer and to be assured that the unique and expert services of Executive will be available to the Company and
that the confidential information and goodwill of the Company will be preserved for its exclusive benefit; and
WHEREAS, the Company desires to employ Executive
pursuant to the terms and conditions set forth in this Agreement, effective as of October 25, 2026 (such date on which this Agreement
becomes effective, the “Effective Date”), and Executive is willing and able to render such services and desires to do so on
the terms and conditions hereinafter set forth herein.
NOW, THEREFORE, in consideration of the above
recitals incorporated herein and the mutual covenants and promises contained herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby expressly acknowledged, the parties agree as follows:
1. Retention and Duties.
(a) The Company hereby agrees
to engage and employ Executive for the Period of Employment (as defined in Section 2) on the terms and conditions expressly set forth
in this Agreement. Executive hereby accepts and agrees to such engagement and employment, on the terms and conditions expressly set forth
in this Agreement.
(b) During the Period of Employment,
Executive shall serve as Chief Executive Officer of the Company. Subject to applicable corporate law, fiduciary duties, stockholder election
requirements and Nasdaq rules, the Company shall take all appropriate corporate actions to appoint Executive as Chairperson of the board
of directors of the Company (the “Board”) effective on the Effective Date and to nominate Executive for reelection to the
Board during the Period of Employment. Executive shall report directly to the Board, with the duties, authority, budget oversight and
decision-making responsibilities customarily exercised by a public biotechnology company chief executive officer and chairperson of the
board, subject to reserved Board matters. Executive’s principal work location shall be Connecticut, with remote/hybrid work permitted
and reasonable business travel to Emeryville and other locations as necessary. Executive shall not be required to relocate. All reasonable
Company travel expenses shall be reimbursed under Section 3(d).
(c) During the Period of Employment,
Executive shall (i) devote substantially all of Executive’s business time, energy and skill to the performance of Executive’s
duties for the Company, (ii) perform such duties in a faithful, effective and efficient manner, and (iii) hold no other employment; provided
that the foregoing shall not prevent Executive from continuing to participate in such charitable, civic, educational, professional, community
or industry affairs or being a member of the board of directors of other public or private companies, as disclosed to and approved in
writing by the Board (including those set forth on Exhibit B hereto), so long as such activities do not, either individually or in the
aggregate, materially interfere or conflict with Executive’s duties hereunder or result in a breach of any restrictive covenant
obligation of Executive. Executive agrees to perform Executive’s duties and responsibilities within and subject to the Company’s
general employment policies and practices, and such other reasonable policies, practices and restrictions as the Company shall from time
to time establish for its similarly situated executives.
(d) Executive hereby represents
to the Company that: (i) the execution and delivery of this Agreement and the performance by Executive of Executive’s duties hereunder
do not and shall not constitute a breach of, conflict with, or otherwise contravene or cause a default under, the terms of any other agreement
or policy to which Executive is a party or otherwise bound or any judgment, order or decree to which Executive is subject; (ii) Executive
has no information (including, without limitation, confidential information and trade secrets) relating to any other person or entity
that would prevent Executive under the terms of any other agreement or arrangement from entering into this Agreement or carrying out Executive’s
duties hereunder, or would give rise to a violation of such other agreement or arrangement by virtue of Executive entering into this Agreement
and carrying out Executive’s duties hereunder; (iii) Executive is not bound by any employment, consulting, non-competition, confidentiality,
trade secret or similar agreement (other than this Agreement) with any other person or entity that would prevent Executive under the terms
of any other agreement or arrangement from entering into this Agreement or carrying out Executive’s duties hereunder, or would give
rise to a violation of such other agreement or arrangement by virtue of Executive entering into this Agreement and carrying out Executive’s
duties hereunder; and (iv) Executive understands the Company will rely upon the accuracy and truth of the representations and warranties
of Executive set forth herein.
2. Period of Employment. The “Period
of Employment” shall be the period commencing on the Effective Date and continuing until Executive’s employment with the Company
terminates pursuant to Section 5. Notwithstanding anything to the contrary in this Agreement, Executive’s employment with the Company
shall be “at will.”
3. Compensation and Reimbursement of Expenses.
(a) Base Salary. Executive’s
starting annual Base Salary shall be US$250,000, payable on the Company’s normal payroll schedule. Base Salary shall increase automatically,
without further Board or Compensation Committee action, to $400,000 when Cumulative Qualifying Funding first exceeds $35,000,000; to $450,000
when it first exceeds $55,000,000; and to $525,000 when it first exceeds $75,000,000. “Cumulative Qualifying Funding” means
the aggregate cash actually received by the Company or its controlled subsidiaries on or after the Effective Date through equity investments
(including PIPEs), strategic investments, grants, licensing or partnership upfront payments and milestone payments, acquisition-related
net cash proceeds, acquired unrestricted cash that becomes available to the Company, and other business-development financing transactions.
Amounts shall count once only, net of amounts returned, refunded or cancelled; announced deal values, contingent unpaid consideration
and undrawn credit facilities do not count until received. Separate tranches count when received; multiple qualifying transactions aggregate.
The increased Base Salary becomes effective on the date the applicable threshold is exceeded and any retroactive payroll difference shall
be paid in the next practicable payroll, no later than 30 days thereafter. Once attained, any Base Salary level is permanent and shall
never be reduced, including as part of an across-the-board reduction, due to later expenditures or declines in cash balance, or otherwise,
without Executive’s express written consent. The Board may increase but shall not decrease Base Salary. The Company shall maintain
and provide Executive on reasonable request an accounting of qualifying receipts. The parties acknowledge that a portion of Base Salary
constitutes consideration for the enforceable covenants under Section 6.
2
(b) Annual Cash Bonus. Executive
shall have an annual target cash bonus opportunity (the “Annual Bonus”) equal to sixty percent (60%) of Base Salary for the
first fiscal year and thereafter no less than fifty-five percent (55%) and up to seventy percent (70%) of Base Salary, with the annual
target percentage established in writing by the Compensation Committee of the Board (the “Compensation Committee”) no later
than 60 days after the start of each fiscal year; absent timely written adjustment, the target shall remain 60%, and no decrease below
a prior approved higher target may occur without Executive’s written consent. The Compensation Committee shall establish objective,
reasonably achievable financial, clinical, operational, strategic-transaction and individual performance objectives after consultation
with Executive. Achievement above target may merit payment above target pursuant to an approved bonus program. Bonuses shall be calculated
using Base Salary actually earned during the fiscal year, accounting for salary accelerators, and shall be paid no later than March 15
of the following year, subject to legally required deferral provisions. Executive shall receive a prorated Annual Bonus for a partial
initial year and, on a termination without Cause or resignation for Good Reason, a prorated target Annual Bonus for the termination year,
payable under Section 5(c). Any Annual Bonus for a completed performance year shall remain payable notwithstanding separation before the
ordinary payment date, except termination for Cause.
(c) Incentive Equity. During
the Period of Employment, Executive will be eligible to receive an annual grant of incentive equity awards pursuant to any plans or arrangements
the Company may have in effect from time to time. The Compensation Committee of the Board will determine in its discretion the terms of
any equity award in accordance with the terms of the Company’s applicable incentive plan or arrangement that may be in effect from
time to time.
(d) Reimbursement of Business Expenses.
The Company shall reimburse reasonable, documented expenses incurred for Company business, including air and ground travel, appropriate
lodging, communications, professional memberships, investor/partner meetings, and reasonable meals and entertainment. Executive may book
reasonable executive-level accommodations consistent with Company resources and business needs. No relocation shall be required. Reimbursement
shall be made within 30 days after submission of documentation (or earlier when required by law); advance approval rules must be reasonable,
disclosed in writing and not applied retroactively.
(e) Clawback Policy. To the extent
required by applicable law or regulation, any applicable stock exchange listing standards or any clawback policy adopted by the Company
pursuant to any such law, regulation or stock exchange listing standards (including, without limitation, the Company’s compensation
recovery policy adopted pursuant to Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule
10D-1 thereunder and Nasdaq Listing Rule 5608, as in effect from time to time), or to comport with good corporate governance practices,
the Annual Bonus and any other incentive compensation granted to Executive (whether pursuant to this Employment Agreement or otherwise,
and including the Initial Option (as defined below)) shall be subject to the provisions of any applicable clawback policies or procedures,
which may provide for forfeiture and/or recoupment of such amounts paid or payable under this Employment Agreement or otherwise, including
incentive equity awards granted to Executive.
3
(f) Initial Option Grant.
(i) Grant. Subject to approval
by the Compensation Committee (which, for purposes of the exemption provided by Rule 16b-3 under the Exchange Act, shall consist solely
of “non-employee directors” within the meaning of such rule), the Company shall grant to Executive an option to purchase one
million (1,000,000) shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) (the “Initial
Option”), under the Company’s 2023 Omnibus Incentive Plan (as amended from time to time, the “Plan”). The Initial
Option shall be granted on the date specified by the Compensation Committee in approving the grant, which is expected to occur on or as
promptly as practicable following the Effective Date (the “Grant Date”); provided that the Compensation Committee may determine
the Grant Date in accordance with the Company’s equity award grant practices, including so that the Grant Date does not fall within
the period beginning four (4) business days before and ending one (1) business day after the filing of a periodic report on Form 10-Q
or Form 10-K, or the filing or furnishing of a current report on Form 8-K that discloses material nonpublic information. Executive acknowledges
that this Agreement does not itself grant any option or other equity award, and that Executive shall have no rights with respect to the
Initial Option unless and until it is approved by the Compensation Committee and evidenced by a written award agreement executed by the
Company and Executive.
(ii) Exercise Price. The Initial
Option shall have a per-share exercise price equal to one hundred percent (100%) of the Fair Market Value (as defined in the Plan) of
a share of Common Stock on the Grant Date, which, for so long as the Common Stock is listed on The Nasdaq Stock Market, shall be the closing
sales price of a share of Common Stock as reported on such exchange on the Grant Date; provided, that if Executive owns (or is deemed
to own under Section 424(d) of the Code (as defined below)) more than ten percent (10%) of the total combined voting power of all classes
of stock of the Company on the Grant Date, the exercise price of any portion of the Initial Option intended to qualify as an incentive
stock option shall be not less than one hundred ten percent (110%) of such Fair Market Value. In no event shall the exercise price be
determined by reference to any date before the Grant Date.
(iii) Type of Option. The Initial
Option shall be designated as an “incentive stock option” within the meaning of Section 422 of the Code to the maximum extent
permitted by Section 422 of the Code (including the $100,000 limitation of Section 422(d) of the Code) and by the incentive stock option
share limit of the Plan, and the remainder of the Initial Option shall be a nonqualified stock option. The Company makes no representation
or warranty that any portion of the Initial Option will qualify as an incentive stock option.
(iv) Vesting. The Initial Option
shall vest and become exercisable as follows, subject to Executive’s continuous service with the Company through each applicable
vesting date: twenty-five percent (25%) of the shares subject to the Initial Option shall vest on the first (1st) anniversary of the Effective
Date (the “Vesting Commencement Date” being the Effective Date), and the remaining seventy-five percent (75%) of the shares
subject to the Initial Option shall vest in thirty-six (36) substantially equal monthly installments on the corresponding day of each
month thereafter, such that the Initial Option shall be fully vested on the fourth (4th) anniversary of the Effective Date. The Initial
Option shall be eligible for accelerated vesting as provided in Section 5(c)(iii) of this Agreement.
4
(v) Term; Post-Termination Exercise.
The Initial Option shall have a maximum term of ten (10) years from the Grant Date (or five (5) years from the Grant Date with respect
to any portion of the Initial Option that is an incentive stock option granted to a holder of more than ten percent (10%) of the total
combined voting power of the Company, if applicable), subject to earlier termination as provided in the Plan and the applicable award
agreement. Except as otherwise provided in Section 3(f)(iv) and Section 5(c)(iii) of this Agreement, any portion of the Initial Option
that is unvested as of the Separation Date shall be forfeited without consideration, and any vested portion shall remain exercisable for
the period following the Separation Date set forth in the Plan and the applicable award agreement.
(vi) Governing Documents. The Initial
Option shall be subject in all respects to the terms and conditions of the Plan and the Company’s standard form of stock option
award agreement, including the provisions of the Plan relating to adjustments upon changes in capitalization and the treatment of awards
in connection with a Change in Control. In the event of any conflict between this Section 3(f) and the Plan, the Plan shall control; provided,
that the accelerated vesting provided under Section 3(f)(iv) and Section 5(c)(iii) of this Agreement shall apply to the Initial Option
to the extent permitted by the Plan.
(vii) Securities Law and Company Policy
Compliance. The Company intends that the shares of Common Stock issuable upon exercise of the Initial Option will be registered under
the Securities Act of 1933, as amended, on a registration statement on Form S-8. Executive acknowledges that, as an executive officer
of the Company, Executive will be subject to (A) the reporting requirements and short-swing profit provisions of Section 16 of the Exchange
Act, (B) the Company’s insider trading policy, including any applicable blackout periods and pre-clearance procedures, as in effect
from time to time, and (C) any applicable restrictions on resale under Rule 144 under the Securities Act of 1933, as amended. Executive
agrees to provide the Company, on a timely basis, with such information as the Company may reasonably request to enable the Company to
assist Executive with Executive’s filings under Section 16 of the Exchange Act and to comply with the Company’s disclosure
obligations under applicable securities laws.
(viii) Tax Matters. The Initial
Option is intended to be exempt from Section 409A as a stock right with an exercise price not less than the fair market value of the underlying
stock on the Grant Date, and shall be interpreted and administered accordingly. Any exercise of the Initial Option and any disposition
of the shares acquired upon exercise shall be subject to applicable tax withholding in accordance with Section 8 of this Agreement and
the Plan. Executive acknowledges that Executive has been advised to consult with Executive’s own tax advisor regarding the tax consequences
of the Initial Option.
5
4. Employee Benefits.
(a) Company Employee Benefit Plans.
During the Period of Employment, Executive and Executive’s eligible dependents shall be eligible to participate in all health, dental,
vision, life, disability and retirement programs available to similarly situated executives of the Company, subject to applicable plan
terms, and to receive benefits no less favorable than those afforded to other senior officers of the Company. The Company may modify generally
applicable plans in compliance with law, but shall not selectively reduce Executive’s contractual compensation or negotiated rights.
The Company shall provide a current written summary of available coverage, premium sharing and eligibility prior to the Effective Date.
(b) Vacation and Other Leave.
During the Period of Employment, Executive shall be eligible to receive paid vacation in accordance with and subject to the Company’s
vacation policies in effect from time to time. Vacations are to be taken at times mutually agreeable to the Company and the Executive.
5. Termination of Employment.
(a) Termination by the Company; Termination
Due to Death. Executive’s employment with the Company and the Period of Employment may be terminated by the Company immediately
upon notice to Executive for an involuntary termination of employment for Cause (as defined below), without Cause or due to Executive’s
Disability (as defined below). Executive’s employment with the Company, and the Period of Employment, shall automatically terminate
upon Executive’s death.
(b) Termination by Executive.
Executive’s employment with the Company, and the Period of Employment, may be terminated by Executive for any reason with no less
than ninety (90) days’ advance written notice to the Company. Upon Executive’s resignation, Executive shall cooperate as reasonably
requested by the Board to effectuate an orderly transition.
(c) Benefits upon Termination.
If Executive’s employment with the Company is terminated during the Period of Employment for any reason by the Company or by Executive,
the Company shall have no further obligation to make or provide to Executive, and Executive shall have no further right to receive or
obtain from the Company, any payments or benefits except as follows:
(i) The Company shall pay Executive
(or, in the event of Executive’s death, Executive’s estate) any Accrued Obligations (as defined below) within the thirty (30)
day period following the date Executive’s employment terminates (the “Separation Date”), or such earlier date as may
be required by applicable law, and Executive shall receive any vested accrued benefits for which Executive remains eligible under the
Company’s employee welfare benefit and retirement plans, payable according to the terms of such plans. Executive and Executive’s
eligible dependents shall be eligible for continued coverage under the group medical care plans provided to employees of the Company in
accordance with the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) and/or state law, subject
to the terms and conditions thereof, and at Executive’s own expense.
6
(ii) If, during the Period of Employment,
Executive’s employment with the Company ends as a result of an involuntary termination by the Company without Cause or Executive’s
resignation for Good Reason other than in connection with a Change in Control, then, in addition to the amounts payable under Section
5(c)(i), subject to Executive’s timely execution and non-revocation of the general release described in Section 5(d) (the “General
Release”) and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve (12) months of Base
Salary (at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good Reason triggered
by a reduction in Base Salary, the rate in effect prior to the reduction), payable in substantially equal installments on each of the
Company’s regular payroll payment dates during the twelve (12) months following the Separation Date; (B) to the extent unpaid as
of the Separation Date, the Annual Bonus for the fiscal year immediately preceding the year in which the Separation Date occurs, payable
at the time such Annual Bonus would otherwise have been paid under Section 3(b); (C) a prorated target Annual Bonus for the fiscal year
in which the Separation Date occurs, payable in a lump sum on the first regular payroll date following the effectiveness of the General
Release; and (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums
for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon
Executive’s eligibility for substantially comparable employer-sponsored coverage ((A) through (D) collectively, the “Severance
Payments”); provided, that no installment or portion of the Severance Payments shall be payable or paid until the expiration of
the applicable revocation period for the General Release. Notwithstanding anything herein to the contrary, if any Severance Payment is
“nonqualified deferred compensation” within the meaning of Section 409A and the period to consider and, if applicable, revoke
the General Release plus the first regular payroll date thereafter spans two calendar years, then no portion of the Severance Payments
shall be paid until the Company’s first payroll payment date in the second calendar year, and any amount not paid prior to such
date due to such restriction shall be paid in a lump sum along with the installment scheduled to be paid on that date.
(iii) If Executive’s employment
is terminated by the Company without Cause or by Executive for Good Reason within the ninety (90) days prior to a Change in Control or
within the twelve (12) months following a Change in Control, then, in addition to the amounts payable under Section 5(c)(i) but in lieu
of the Severance Payments payable under Section 5(c)(ii), subject to Executive’s timely execution and non-revocation of the General
Release and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve (12) months of Base Salary
(at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good Reason triggered by a reduction
in Base Salary, the rate in effect prior to the reduction), payable in a lump sum on the first regular payroll date following the effectiveness
of the General Release; (B) to the extent unpaid as of the Separation Date, the Annual Bonus for the fiscal year immediately preceding
the year in which the Separation Date occurs, payable at the time such Annual Bonus would otherwise have been paid under Section 3(b);
(C) a lump-sum payment, payable on the first regular payroll date following the effectiveness of the General Release, equal to one hundred
percent (100%) of Executive’s target Annual Bonus for the fiscal year in which the Separation Date occurs (which amount shall not
be prorated); (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums
for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon
Executive’s eligibility for substantially comparable employer-sponsored coverage; and (E) acceleration of one hundred percent (100%)
of Executive’s outstanding unvested equity awards as of the Separation Date; provided, however, that if an outstanding equity award
is to vest and/or the amount of the equity award to vest is to be determined based on the achievement of performance criteria, then the
equity award will vest as to one hundred percent (100%) of the amount of the equity award assuming the performance criteria had been achieved
at target levels for the relevant performance period(s), unless otherwise provided in the applicable award agreement ((A) through (E)
collectively, the “Change in Control Severance Payments”). For a qualifying termination occurring prior to a Change in Control,
any equity award that was forfeited on the Separation Date shall be treated as having remained outstanding through the closing of the
Change in Control for purposes of this clause (E), to the extent permitted by the applicable plan.
7
(iv) A material, finally determined
breach by Executive of enforceable continuing obligations under Section 6, after written notice and a reasonable opportunity to cure where
curable, may permit only prospective suspension of amounts not legally protected, subject to applicable law and judicial review. Accrued
wages, earned bonuses, vested equity and indemnification rights shall not be forfeited solely by allegation of breach.
(d) General Release. This Section
5(d) shall apply notwithstanding anything else in this Agreement to the contrary. As a condition precedent to any Company obligation to
Executive pursuant to Section 5(c)(ii) or 5(c)(iii), as applicable, Executive shall provide the Company with a valid, executed General
Release in a customary, standard form of the Company, which shall not contain any more onerous restrictive covenants than those contained
herein, and not revoke such General Release prior to the expiration of any revocation rights afforded to Executive by applicable law.
The Company shall provide Executive with the General Release prior to the Separation Date, and Executive must deliver the executed General
Release to the Company within twenty-one (21) days (or, if greater, the minimum period required by applicable law) after the Separation
Date, failing which Executive will forfeit all rights to the payments and benefits set forth in Section 5(c)(ii) or 5(c)(iii) (as applicable).
(e) Exclusive Remedy. Section
5(c) provides the parties’ agreed contractual severance treatment but shall not preclude Executive from enforcing this Agreement,
exercising vested equity rights, recovering accrued salary or earned bonuses, asserting indemnification or advancement rights, seeking
relief for discrimination, retaliation or other statutory violations, or pursuing benefits expressly protected by applicable law. Nothing
herein requires waiver of claims that cannot legally be waived.
(f) Certain Defined Terms. As
used in this Agreement:
(i) “Accrued Obligations”
means (A) any Base Salary that had accrued but had not been paid (including any amount for accrued and unused vacation time payable in
accordance with the Company’s vacation policy then in effect or applicable law) on or before the Separation Date, (B) any reimbursement
due to Executive pursuant to Section 3(d) for expenses incurred by Executive on or before the Separation Date and (C) any other vested
benefits or vested amounts due and owed to Executive under the terms of any plan, program or arrangement of the Company.
8
(ii) “Cause” means
(A) final conviction of or guilty/nolo contendere plea to a felony involving dishonesty or material harm to the Company or its affiliates
or subsidiaries (the “Company Group” and each a “Company Group Member”); (B) willful fraud, theft or embezzlement
against the Company Group; (C) willful and material failure to perform lawful duties as Chief Executive Officer after a specific written
demand identifying the deficiency and at least thirty (30) days to cure where curable; (D) willful and material breach of this Agreement
or a material written Company policy applicable to senior executives, after thirty (30) days’ written notice and opportunity to
cure where curable; or (E) willful misconduct or gross negligence resulting in demonstrable material harm to the Company Group. An act
is not “willful” if undertaken in good faith with a reasonable belief that it served the Company’s interests. No termination
for Cause shall occur without written particulars and a reasonable opportunity for Executive and counsel to respond to disinterested Board
members; Executive shall recuse herself from the Board’s determination. Cause shall not include mere business disagreement, an unsuccessful
good- faith strategic decision, or failure to meet results in the absence of misconduct. Notwithstanding the foregoing, no Cause shall
exist unless the Company has provided the Executive written notice detailing the event constituting Cause and, to the extent the event
is reasonably susceptible to cure, the Executive does not cure such event within thirty (30) days of the receipt of such notice.
(iii) “Change in Control”
shall have the meaning as defined (or as the analogous term is defined) in the Company’s incentive plan(s) under which equity awards
are or have been granted to Executive from time to time.
(iv) “Disability” means
a physical or mental impairment that renders Executive unable to perform the essential functions of Executive’s employment with
the Company, even with reasonable accommodation that does not impose an undue hardship on the Company, for ninety (90) days (whether or
not continuous) during any period of one-hundred eighty (180) consecutive days, unless a longer period is required by federal or state
law, in which case that longer period would apply.
(v) “Good Reason” means,
without Executive’s prior written consent: (A) any reduction in Base Salary (except for a decrease of not more than ten percent
(10%) in connection with any across-the-board reduction impacting substantially all executives of the Company); (B) a material decrease
in the target Annual Bonus opportunity; (C) material diminution of Executive’s responsibilities, authority or status as Chief Executive
Officer; (D) required relocation of Executive’s principal work location outside Connecticut or removal of the agreed Connecticut-based
remote/hybrid arrangement; (E) material breach of this Agreement by the Company, including repeated failure to pay amounts when due; or
(F) failure of a successor to assume this Agreement. Executive shall notify the Company within ninety (90) days after learning of the
condition, the Company shall have thirty (30) days to cure, and Executive shall terminate within ninety (90) days following expiration
of the cure period if uncured.
(vi) “Section 409A”
means Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations, rules and other guidance
promulgated thereunder.
9
(g) Officer/Board/Committee Resignations.
Upon termination of employment, Executive shall resign from Company officer positions, but a resignation from the Board or the position
of Chairperson of the Board shall be subject to applicable law, the Company’s governing documents and any separately negotiated
Board transition arrangement. No deemed resignation shall deprive Executive of rights arising from a Company-initiated removal that constitutes
Good Reason, or of accrued equity, indemnification or advancement rights.
(h) Section 409A.
(i) It is the intention of the
parties that Executive’s performance of the services under this Agreement and payments to Executive under this Agreement shall not
implicate Section 409A. In the event that Executive’s performance of the services or any payment due to the Executive under this
Agreement would subject Executive to the additional tax and interest imposed by Section 409A, or any interest or penalties with respect
to such additional tax, the Company shall modify this Agreement to make it compliant with Section 409A and maintain the value of the payments
and benefits under the Agreement. In no event, however, shall the Company be liable for any tax, interest or penalty imposed on Executive
under Section 409A or any damages for failing to comply with Section 409A.
(ii) If at the time of the Executive’s
termination of employment, the Executive is a “specified employee,” under Section 409A, any and all amounts payable under
this Agreement on account of such termination of employment that would (but for this provision) be payable within six (6) months following
the date of termination, shall instead be paid on the next business day following the expiration of such six (6) month period or, if earlier,
the date of the Executive’s death; except (A) to the extent of amounts that do not constitute a deferral of compensation within
the meaning of Section 409A; (B) benefits which qualify as excepted welfare benefits pursuant to Section 409A-1(a)(5); or (C) other amounts
or benefits that are not subject to the requirements of Section 409A. Each payment made under this Agreement shall be treated as a separate
payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments.
(iii) Any reimbursement payment
or in-kind benefit due to Executive pursuant to Section 3(d), to the extent that such reimbursements or in-kind benefits are taxable to
Executive, shall be paid on or before the last day of Executive’s taxable year following the taxable year in which the related expense
was incurred. Executive agrees to provide prompt notice to the Company of any such expenses (and any other documentation that the Company
may reasonably require to substantiate such expenses) in order to facilitate the Company’s timely reimbursement of the same. Reimbursements
and in-kind benefits pursuant to Section 3(d) are not subject to liquidation or exchange for another benefit and the amount of such benefits
that Executive receives in one taxable year shall not affect the amount of such reimbursements or benefits that Executive receives in
any other taxable year.
(iv) For purposes of Section 409A,
Executive’s right to receive any installment payments hereunder shall be treated as a right to receive a series of separate and
distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (e.g., payment
shall be made within thirty (30) days following the date of termination), the actual date of payment within the specified period shall
be within the sole discretion of the Company.
10
6. Restrictive Covenants.
(a) Non-Disclosure and Non-Use
of Confidential Information.
(i) Executive agrees that during
the Period of Employment and following the termination thereof for any reason, the Executive shall not, and shall cause his affiliates
and representatives not to, disclose to any individual or natural person, partnership (including a limited liability partnership), corporation,
limited liability company, association, joint stock company, trust, joint venture, unincorporated organization or governmental authority
(each, a “Person”), except (i) to the Executive’s legal, financial, tax or accounting advisors, or (ii) as compelled
by law, any Confidential Information for any reason or purpose whatsoever, and the Executive shall not, and shall cause Executive’s
affiliates or representatives not to, make use of any of the Confidential Information for their own purposes or for the benefit of any
Person except any Company Group Member. In the event that Executive or any of Executive’s affiliates or representatives are compelled
by law to disclose any Confidential Information, the Executive shall promptly provide written notice to the Company of the request or
requirement so that the Company may seek (at the Company’s sole cost and expense) an appropriate protective order or waive compliance
with the provisions of this Section 6(a). If, in the absence of a protective order or the receipt of a waiver hereunder, the Executive
or any of the Executive’s affiliates or representatives are compelled by law to disclose any Confidential Information to any tribunal,
the Executive or the Executive’s affiliates, as applicable, may disclose the Confidential Information to the tribunal; provided,
that the Executive or the Executive’s affiliates, as applicable, shall use commercially reasonable efforts to obtain, at the request
and sole expense of the Company, an order or other assurance that confidential treatment shall be accorded to such portion of the Confidential
Information required to be disclosed as the Company shall designate.
(ii) For purposes of this Agreement,
“Confidential Information” shall mean any information of a confidential or proprietary nature concerning the business or affairs
of the Company Group; provided however, “Confidential Information” shall not include information which (i) is or becomes generally
available to the public other than as a result of disclosure by Executive or any of the Executive’s affiliates to the receiving
party in violation of this Agreement or (ii) becomes available to the Executive or any of the Executive’s affiliates on a non-confidential
basis from a source other than any Company Group Member, so long as such source is not known by the Executive to be bound by a confidentiality
agreement with any of the foregoing prohibiting such disclosure.
(iii) For the avoidance of doubt,
this Section 6(a) does not prohibit or restrict Executive (or Executive’s attorney) from responding to any inquiry about this Agreement
or its underlying facts and circumstances by the Securities and Exchange Commission, the Financial Industry Regulatory Authority, or any
other self-regulatory organization or governmental authority, or making other disclosures that are protected under the whistleblower provisions
of federal law or regulation. Executive understands and acknowledges that Executive does not need the prior authorization of the Company
to make any such reports or disclosures and that Executive is not required to notify the Company that Executive has made such reports
or disclosures.
11
(iv) Notwithstanding anything in
this Section 6(a) or elsewhere in this Agreement to the contrary, Executive understands that Executive may, pursuant to the U.S. Defend
Trade Secrets Act of 2016 (“DTSA”), without informing the Company prior to any such disclosure, disclose Confidential Information
(A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the
purpose of reporting or investigating a suspected violation of law or (B) in a complaint or other document filed in a lawsuit or other
proceeding, if such filing is made under seal. Additionally, without informing the Company prior to any such disclosure, if Executive
files a lawsuit against the Company for retaliation for reporting a suspected violation of law, Executive may, pursuant to the DTSA, disclose
Confidential Information to Executive’s attorney and use the Confidential Information in the court proceeding or arbitration, provided
that Executive files any document containing the Confidential Information under seal and does not otherwise disclose the Confidential
Information, except pursuant to court order. Without prior authorization of the Company, however, the Company does not authorize Executive
to disclose to any third party (including any government official or any attorney Executive may retain) any communications that are covered
by the Company’s attorney-client privilege.
(b) Intellectual Property Rights.
(i) Executive hereby assigns, transfers,
and conveys to the Company all of Executive’s right, title and interest in and to all Work Product (as defined below). Executive
agrees that all Work Product belongs in all instances to the Company. Executive will promptly disclose such Work Product to the Company
and perform all actions reasonably requested by the Company (whether during or after the Period of Employment) to establish and confirm
the Company’s ownership of such Work Product (including, without limitation, the execution and delivery of assignments, consents,
powers of attorney, and other instruments) and to provide reasonable assistance to the Company (whether during or after the Period of
Employment) in connection with the prosecution of any applications for patents, trademarks, trade names, service marks or reissues thereof
or in the prosecution or defense of interferences relating to any Work Product. Executive recognizes and agrees that the Work Product,
to the extent copyrightable, constitutes works for hire under the copyright laws of the United States.
(ii) For purposes of this Agreement,
“Work Product” means all inventions, innovations, improvements, technical information, systems, software developments, methods,
designs, analyses, drawings, reports, service marks, trademarks, trade names, trade dress, logos and all similar or related information
(whether patentable or unpatentable) which relates to the actual business, operations, research and development, or existing or future
products or services of the Company Group and which are conceived, developed, or made by Executive (whether or not during usual business
hours and whether or not alone or in conjunction with any other person) during the Period of Employment together with all patent applications,
letters patent, trademark, trade name, and service mark applications or registrations, copyrights and reissues thereof that may be granted
for or upon any of the foregoing. Notwithstanding the foregoing, “Work Product” shall not include the patents and other assets
set forth on Exhibit A hereto. Executive hereby represents and warrants that the patents and other assets owned by Executive set forth
on Exhibit A are not related in any way to the Company Group, except as stated therein.
12
(c) Non-Solicitation and Non-Interference.
During the Period of Employment Executive will not, and will cause Executive’s affiliates not to use confidential information to,
directly or indirectly through any other Person (whether as an officer, manager, director, employee, partner, consultant, holder of equity
or debt investment, lender or any other manner or capacity): (i) directly or indirectly contact, induce or solicit (or assist any Person
to contact, induce or solicit) for employment any person who is, or within the preceding twelve (12) months was, an executive employed
by a Company Group Member; or (ii) induce or attempt to induce any customer, supplier, or licensee of the Company Group within the preceding
twelve (12) months to cease doing business with the Company Group or in any way interfere with the relationship between the Company Group
and any such customer, supplier, or licensee.
(d) Mutual Non-Disparagement.
During and after the Period of Employment, Executive shall not knowingly make materially false statements of fact intended to harm the
Company or its officers or directors, and the Company shall instruct its directors and senior executive officers not to knowingly make
materially false statements of fact intended to harm Executive. This provision does not restrict truthful testimony, good-faith regulatory
reports, legal claims, lawful disclosures, protected concerted activity, statements to professional advisers or other speech protected
by law.
7. Acknowledgment and Enforcement of Covenants.
(a) Acknowledgment. Executive
acknowledges that Executive has become familiar, or will become familiar, with the Company Group Members’ trade secrets and with
other Confidential Information concerning the Company Group Members and their respective predecessors, successors, customers, and suppliers,
and that Executive’s services are of special, unique, and extraordinary value to the Company. Executive acknowledges and agrees
that the Company would not enter into this Agreement, providing for compensation and other benefits to Executive on the terms and conditions
set forth herein, but for Executive’s agreements herein (including those set forth in Section 6). Furthermore, Executive acknowledges
and agrees that the Company will be providing Executive with additional special knowledge after the Effective Date, with such special
knowledge to include additional Confidential Information and trade secrets. Executive agrees that the covenants set forth in Section 6
(collectively, the “Restrictive Covenants”) are reasonable and necessary to protect the Company Group’s trade secrets
and other Confidential Information, proprietary information, goodwill, stable workforce, and customer relations.
(b) Representations. Executive
acknowledges the legitimate need to protect the Company Group’s Confidential Information and trade secrets, but makes no advance
waiver of any statutory protections or right to challenge an unlawful, unreasonable or unenforceable restrictive covenant. The parties
intend enforcement only to the extent permitted under applicable law, including California law where applicable.
13
(c) Enforcement. Executive acknowledges
and agrees that money damages would not be an adequate remedy for any breach or threatened breach of the provisions of the Restrictive
Covenants and that the Company or any of its successors or assigns shall, in addition to any other rights and remedies existing in their
favor, be entitled to specific performance, injunctive and/or other relief from any court of competent jurisdiction in order to enforce
or prevent any violations of the Restrictive Covenants (including the extension of the restricted periods set forth in Section 6 by a
period equal to the length of any legal proceeding, arbitration, or other action necessary to stop such violation), provided, that Executive
is found to have been in violation of the Restrictive Covenants by a court of competent jurisdiction. Any injunction shall be available
without the posting of any bond or other security. In the event of an alleged breach or violation by Executive of any Restrictive Covenant,
the restricted period will be tolled for the Executive until such alleged breach or violation is resolved; provided, that if Executive
is found to have not violated the Restrictive Covenants, then the restricted period will not be deemed to have been tolled.
(d) Severability. If a court
of competent jurisdiction determines any Restrictive Covenant unenforceable, the court may enforce any lawful severable portion to the
extent permitted by applicable law, without enlarging the covenant. Executive retains the right to contest interpretation or enforceability
and to assert all lawful defenses. No provision shall require Executive to waive statutory rights or prevent lawful professional activity.
8. Withholding Taxes/Authorized Deductions.
Notwithstanding anything herein to the contrary, the Company may withhold (or cause to be withheld) from any amounts otherwise due or
payable under or pursuant to this Agreement such federal, state and local income, social security, employment or other taxes as may be
required to be withheld pursuant to any applicable law or regulation, and make such deductions as may be applicable pursuant to the Company’s
policies and employee benefit plans.
9. Cooperation. During and after the Period
of Employment, Executive shall cooperate fully with any investigation or inquiry by the Company, or any governmental or regulatory agency
or body concerning the Company or any other member of the Company, provided that the Company shall reimburse Executive’s reasonable
expenses incurred in providing such cooperation (including, without limitation, attorneys’ fees and lodging and meals) subject to
Executive’s delivery of written notice to the Company prior to the time such expenses are incurred.
10. Governing Law. This Agreement will
be governed by and construed in accordance with the laws of the State of California without giving effect to any choice or conflict of
law provision or rule (whether of the State of California or any other jurisdiction) that would cause the application of the laws of any
jurisdiction other than the State of California.
11. Consent to Jurisdiction. Subject to
mandatory statutory venue and jurisdiction rules, the parties consent to the state and federal courts located in California or Connecticut
for claims arising from this Agreement, at Executive’s election for claims she brings, and waive objections to personal jurisdiction
where lawful. Either party may seek provisional equitable relief in an otherwise competent court, without waiving available defenses or
statutory rights. Service of process shall comply with applicable law. Nothing herein limits a right to pursue a claim before an administrative
agency.
12. Waiver of Jury Trial. Each of the parties
hereto hereby irrevocably waives all right to trial by jury in any action, proceeding or counterclaim arising out of or relating to this
Agreement.
14
13. Severability. It is the desire and
intent of the parties hereto that the provisions of this Agreement be enforced to the fullest extent permissible under the laws and public
policies applied in each jurisdiction in which enforcement is sought. Accordingly, if any particular provision of this Agreement shall
be adjudicated by a court of competent jurisdiction to be invalid, prohibited or unenforceable under applicable law, such provision, as
to such jurisdiction, shall be ineffective without invalidating the remaining provisions of this Agreement or affecting the validity or
enforceability of such provision in any other jurisdiction.
14. Indemnification. To the fullest extent
permitted by Delaware law and the Company’s governing documents, the Company shall indemnify Executive for actions taken in good
faith in her capacity as an officer, director and Chairperson of the Board, and shall advance reasonable defense expenses promptly upon
appropriate undertaking where legally required. Before or at commencement of the Period of Employment, the Company and Executive shall
enter into a separate written indemnification agreement no less favorable than those of other directors. The Company shall maintain commercially
reasonable directors’ and officers’ liability insurance covering Executive on terms no less favorable than other senior officers
and directors throughout service and, for claims relating to such service, appropriate run-off/tail coverage for at least six (6) years
following a Change in Control, subject to commercially reasonable availability and cost. Executive may use independent counsel at Company
expense when an actual material conflict warrants it, to the extent legally permitted. These obligations survive termination.
15. Entire Agreement; Amendment. This Agreement,
the award agreement(s) evidencing the Initial Option and any other equity awards, the separate indemnification agreement and the completed
Exhibits A and B hereto embody the entire agreement of the parties hereto respecting the matters within their scope and supersede all
prior agreements, whether written or oral, that directly or indirectly bear upon the subject matter hereof. This Agreement may not be
amended, modified or changed (in whole or in part), except by written agreement executed by Executive and a duly authorized officer of
the Company following any required approval of the Board or the Compensation Committee.
16. Waiver. No waiver of any provision
of this Agreement will constitute or be deemed to constitute a waiver of any other provision of this Agreement, nor will any such waiver
constitute a continuing wavier unless otherwise expressly provided.
17. Successors and Assigns. This Agreement
cannot be assigned by the Company without the prior written consent of Executive, other than (a) an assignment to an affiliate of the
Company made as part of an internal reorganization applicable to employees of the Company generally or (b) to any successor or assign
(whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of
the Company, and shall be binding and inure to the benefit of the Company, its successors and any permitted assigns. No right, obligation
or duty of this Agreement may be assigned by Executive without the prior written consent of the Company.
15
18. Notices. Any notice provided for in
this Agreement must be in writing and must be either personally delivered, transmitted via email, mailed by first class mail (postage
prepaid and return receipt requested) or sent by reputable overnight courier service (charges prepaid) to the recipient at the address
below indicated or at such other address or to the attention of such other person as the recipient party has specified by prior written
notice to the sending party. Notices will be deemed to have been given hereunder and received when delivered personally, when received
if transmitted via telecopier or email, five days after deposit in the U.S. mail and one day after deposit with a reputable overnight
courier service.
If to the Company:
Estrella Immunopharma, Inc.
5858 Horton Street, Suite 370
Emeryville, CA 94608
Attention: Chief Financial Officer
If to Executive, to the address most recently
on file in the payroll records of the Company.
19. Section 280G. Payments under this Agreement
shall be made without regard to whether the deductibility of such payments (or any other payments to or for the benefit of the Executive)
would be limited or precluded by Section 280G of the Code without regard to whether such payments (or any other payments) would subject
the Executive to the federal excise tax levied on certain “excess parachute payments” under Section 4999 of the Code; provided,
that if the total of all payments to or for the benefit of the Executive (whether under this Agreement or otherwise), after reduction
for all state and federal taxes (including the tax described in Section 4999 of the Code, if applicable) with respect to such payments
(“Executive’s Total After-Tax Payments”), would be increased by the limitation or elimination of any payment under this
Agreement, amounts payable under this Agreement shall be reduced to the extent, and only to the extent, necessary to maximize the Executive’s
Total After-Tax Payments. The determination as to whether and to what extent payments under this Agreement are required to be reduced
in accordance with the preceding sentence shall be made at the Company’s expense by a nationally recognized accounting firm after
considering in good faith all available exemptions, including a fair valuation of reasonable compensation for services rendered by Executive
and a fair valuation for any post-employment covenants.
20. Legal Counsel; Mutual Drafting. Each
party recognizes that this is a legally binding contract and acknowledges and agrees that they have had the opportunity to consult with
legal counsel of their choice. Each party has cooperated in the drafting, negotiation and preparation of this Agreement. Hence, in any
construction to be made of this Agreement, the same shall not be construed against either party on the basis of that party being the drafter
of such language. Executive agrees and acknowledges that Executive has read and understands this Agreement, is entering into it freely
and voluntarily, and has been advised to seek counsel prior to entering into this Agreement and has had ample opportunity to do so.
21. Counterparts. This Agreement may be
executed in any number of counterparts, each of which shall be deemed an original as against any party whose signature appears thereon,
and all of which together shall constitute one and the same instrument.
[Signatures on Following Page]
16
IN WITNESS WHEREOF, the Company and Executive
have executed this Agreement as of the date first written above.
“COMPANY”
Estrella Immunopharma, Inc.
By:
/s/ Peter Xu
Name:
Peter Xu
Title:
Chief Financial Officer
“EXECUTIVE”
/s/ Cynthia Pussinen
Cynthia Pussinen
[Signature Page to Employment Agreement]
EXHIBIT A
EXCLUDED FROM WORK PRODUCT
☒ I have no inventions.
☐ The following is a complete list of all pre-existing intellectual
property and other assets to be excluded from the definition of Work Product relative to the subject matter of my employment with the
Company that have been created by me, alone or jointly with others, prior to the Effective Date, which might relate to the Company Group’s
present business:
☐ Additional sheets attached.
Executive:
/s/ Cynthia Pussinen
Date: October 25, 2026
Cynthia Pussinen
EXHIBIT B
PREAPPROVED OUTSIDE ACTIVITIES
The following directorships, advisory roles and
other professional commitments of Executive have been disclosed to and approved by the Board for purposes of Section 1(c) of the Agreement:
1. Board Director, Xelcis Bio
EX-10.2 — AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND CHENG LIU, PH.D
EX-10.2
Filename: ea031020901ex10-2.htm · Sequence: 3
Exhibit 10.2
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT
This Amendment No. 1 to Employment Agreement (this
“Amendment”) is made and entered into effective as of October 25, 2026 (the “Amendment Effective Date”), by and
between Estrella Immunopharma, Inc., a Delaware corporation (the “Company”), and Cheng Liu (“Executive”). Capitalized
terms used but not defined in this Amendment have the meanings given to them in the Agreement (as defined below).
WHEREAS, the Company and Executive are parties
to that certain Employment Agreement dated as of November 1, 2024 (the “Agreement”); and
WHEREAS, the Company and Executive desire to amend
the Agreement as set forth herein, and the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”)
and the Board of Directors of the Company (the “Board”) have approved this Amendment.
NOW, THEREFORE, in consideration of the mutual
covenants herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
agree as follows:
1. Position. Section 1(b) of the Agreement
is amended and restated in its entirety to read as follows:
“(b) During the Period
of Employment, Executive shall serve as President and Chief Scientific Officer of the Company and shall have the powers, authorities and
duties customarily vested in such offices in the industry of the Company and as reasonably determined by the Board from time to time.
Executive shall continue to serve as a member of the Board, subject to the Company’s Certificate of Incorporation and Bylaws and
applicable law.”
Executive acknowledges and consents to the foregoing
change in position and to the appointment of another individual as Chief Executive Officer of the Company, and agrees that none of the
foregoing constitutes Good Reason under the Agreement as in effect before or after this Amendment.
2. Compensation. Sections 3(a), 3(b), 3(d)
and 3(e) of the Agreement are amended and restated in their entirety to read as follows, and Section 3(c) of the Agreement is unchanged:
“(a) Base Salary. Executive’s
current annual Base Salary is US$250,000, payable on the Company’s normal payroll schedule. Base Salary shall increase automatically,
without further Board or Compensation Committee action, to $400,000 when Cumulative Qualifying Funding first exceeds $35,000,000; to $450,000
when it first exceeds $55,000,000; and to $525,000 when it first exceeds $75,000,000. “Cumulative Qualifying Funding” means
the aggregate cash actually received by the Company or its controlled subsidiaries on or after the Amendment Effective Date (as defined
in Amendment No. 1 to this Agreement) through equity investments (including PIPEs), strategic investments, grants, licensing or partnership
upfront payments and milestone payments, acquisition-related net cash proceeds, acquired unrestricted cash that becomes available to the
Company, and other business-development financing transactions. Amounts shall count once only, net of amounts returned, refunded or cancelled;
announced deal values, contingent unpaid consideration and undrawn credit facilities do not count until received. Separate tranches count
when received; multiple qualifying transactions aggregate. The increased Base Salary becomes effective on the date the applicable threshold
is exceeded and any retroactive payroll difference shall be paid in the next practicable payroll, no later than 30 days thereafter. Once
attained, any Base Salary level is permanent and shall never be reduced, including as part of an across-the-board reduction, due to later
expenditures or declines in cash balance, or otherwise, without Executive’s express written consent. The Board may increase but
shall not decrease Base Salary. The Company shall maintain and provide Executive on reasonable request an accounting of qualifying receipts.
The parties acknowledge that a portion of Base Salary constitutes consideration for the enforceable covenants under Section 6.
(b) Annual Cash Bonus. Executive
shall have an annual target cash bonus opportunity (the “Annual Bonus”) equal to sixty percent (60%) of Base Salary for the
fiscal year ending December 31, 2026 and thereafter no less than fifty-five percent (55%) and up to seventy percent (70%) of Base Salary,
with the annual target percentage established in writing by the Compensation Committee of the Board (the “Compensation Committee”)
no later than 60 days after the start of each fiscal year; absent timely written adjustment, the target shall remain 60%, and no decrease
below a prior approved higher target may occur without Executive’s written consent. The Compensation Committee shall establish objective,
reasonably achievable financial, clinical, operational, strategic-transaction and individual performance objectives after consultation
with Executive. Achievement above target may merit payment above target pursuant to an approved bonus program. Bonuses shall be calculated
using Base Salary actually earned during the fiscal year, accounting for salary accelerators, and shall be paid no later than March 15
of the following year, subject to legally required deferral provisions. On a termination without Cause or resignation for Good Reason,
Executive shall receive a prorated target Annual Bonus for the termination year, payable under Section 5(c). Any Annual Bonus for a completed
performance year shall remain payable notwithstanding separation before the ordinary payment date, except termination for Cause.
(d) Reimbursement of Business
Expenses. The Company shall reimburse reasonable, documented expenses incurred for Company business, including air and ground travel,
appropriate lodging, communications, professional memberships, investor/partner meetings, and reasonable meals and entertainment. Executive
may book reasonable executive-level accommodations consistent with Company resources and business needs. No relocation shall be required.
Reimbursement shall be made within 30 days after submission of documentation (or earlier when required by law); advance approval rules
must be reasonable, disclosed in writing and not applied retroactively.
(e) Clawback Policy. To the extent
required by applicable law or regulation, any applicable stock exchange listing standards or any clawback policy adopted by the Company
pursuant to any such law, regulation or stock exchange listing standards (including, without limitation, the Company’s compensation
recovery policy adopted pursuant to Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule
10D-1 thereunder and Nasdaq Listing Rule 5608, as in effect from time to time), or to comport with good corporate governance practices,
the Annual Bonus and any other incentive compensation granted to Executive (whether pursuant to this Employment Agreement or otherwise)
shall be subject to the provisions of any applicable clawback policies or procedures, which may provide for forfeiture and/or recoupment
of such amounts paid or payable under this Employment Agreement or otherwise, including incentive equity awards granted to Executive.”
3. Employee Benefits. Section 4(a) of the
Agreement is amended and restated in its entirety to read as follows:
“(a) Company Employee Benefit
Plans. During the Period of Employment, Executive and Executive’s eligible dependents shall be eligible to participate in all health,
dental, vision, life, disability and retirement programs available to similarly situated executives of the Company, subject to applicable
plan terms, and to receive benefits no less favorable than those afforded to other senior officers of the Company. The Company may modify
generally applicable plans in compliance with law, but shall not selectively reduce Executive’s contractual compensation or negotiated
rights. The Company shall provide a current written summary of available coverage, premium sharing and eligibility upon Executive’s
request.”
2
4. Severance. Sections 5(c)(ii), 5(c)(iii)
and 5(c)(iv) of the Agreement are amended and restated in their entirety to read as follows, and Section 5(c)(v) of the Agreement is deleted:
“(ii) If, during the Period
of Employment, Executive’s employment with the Company ends as a result of an involuntary termination by the Company without Cause
or Executive’s resignation for Good Reason other than in connection with a Change in Control, then, in addition to the amounts payable
under Section 5(c)(i), subject to Executive’s timely execution and non-revocation of the general release described in Section 5(d)
(the “General Release”) and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve
(12) months of Base Salary (at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good
Reason triggered by a reduction in Base Salary, the rate in effect prior to the reduction), payable in substantially equal installments
on each of the Company’s regular payroll payment dates during the twelve (12) months following the Separation Date; (B) to the extent
unpaid as of the Separation Date, the Annual Bonus for the fiscal year immediately preceding the year in which the Separation Date occurs,
payable at the time such Annual Bonus would otherwise have been paid under Section 3(b); (C) a prorated target Annual Bonus for the fiscal
year in which the Separation Date occurs, payable in a lump sum on the first regular payroll date following the effectiveness of the General
Release; and (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums
for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon
Executive’s eligibility for substantially comparable employer-sponsored coverage ((A) through (D) collectively, the “Severance
Payments”); provided, that no installment or portion of the Severance Payments shall be payable or paid until the expiration of
the applicable revocation period for the General Release. Notwithstanding anything herein to the contrary, if any Severance Payment is
“nonqualified deferred compensation” within the meaning of Section 409A and the period to consider and, if applicable, revoke
the General Release plus the first regular payroll date thereafter spans two calendar years, then no portion of the Severance Payments
shall be paid until the Company’s first payroll payment date in the second calendar year, and any amount not paid prior to such
date due to such restriction shall be paid in a lump sum along with the installment scheduled to be paid on that date.
(iii) If Executive’s employment
is terminated by the Company without Cause or by Executive for Good Reason within the ninety (90) days prior to a Change in Control or
within the twelve (12) months following a Change in Control, then, in addition to the amounts payable under Section 5(c)(i) but in lieu
of the Severance Payments payable under Section 5(c)(ii), subject to Executive’s timely execution and non-revocation of the General
Release and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve (12) months of Base Salary
(at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good Reason triggered by a reduction
in Base Salary, the rate in effect prior to the reduction), payable in a lump sum on the first regular payroll date following the effectiveness
of the General Release; (B) to the extent unpaid as of the Separation Date, the Annual Bonus for the fiscal year immediately preceding
the year in which the Separation Date occurs, payable at the time such Annual Bonus would otherwise have been paid under Section 3(b);
(C) a lump-sum payment, payable on the first regular payroll date following the effectiveness of the General Release, equal to one hundred
percent (100%) of Executive’s target Annual Bonus for the fiscal year in which the Separation Date occurs (which amount shall not
be prorated); (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums
for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon
Executive’s eligibility for substantially comparable employer-sponsored coverage; and (E) acceleration of one hundred percent (100%)
of Executive’s outstanding unvested equity awards as of the Separation Date; provided, however, that if an outstanding equity award
is to vest and/or the amount of the equity award to vest is to be determined based on the achievement of performance criteria, then the
equity award will vest as to one hundred percent (100%) of the amount of the equity award assuming the performance criteria had been achieved
at target levels for the relevant performance period(s), unless otherwise provided in the applicable award agreement ((A) through (E)
collectively, the “Change in Control Severance Payments”). For a qualifying termination occurring prior to a Change in Control,
any equity award that was forfeited on the Separation Date shall be treated as having remained outstanding through the closing of the
Change in Control for purposes of this clause (E), to the extent permitted by the applicable plan.
3
(iv) A material, finally determined
breach by Executive of enforceable continuing obligations under Section 6, after written notice and a reasonable opportunity to cure where
curable, may permit only prospective suspension of amounts not legally protected, subject to applicable law and judicial review. Accrued
wages, earned bonuses, vested equity and indemnification rights shall not be forfeited solely by allegation of breach.”
5. Exclusive Remedy. Section 5(e) of the
Agreement is amended and restated in its entirety to read as follows:
“(e) Exclusive Remedy.
Section 5(c) provides the parties’ agreed contractual severance treatment but shall not preclude Executive from enforcing this Agreement,
exercising vested equity rights, recovering accrued salary or earned bonuses, asserting indemnification or advancement rights, seeking
relief for discrimination, retaliation or other statutory violations, or pursuing benefits expressly protected by applicable law. Nothing
herein requires waiver of claims that cannot legally be waived.”
6. Certain Defined Terms. Sections 5(f)(ii)
and 5(f)(v) of the Agreement are amended and restated in their entirety to read as follows:
“(ii) “Cause”
means (A) final conviction of or guilty/nolo contendere plea to a felony involving dishonesty or material harm to the Company or its affiliates
or subsidiaries (the “Company Group” and each a “Company Group Member”); (B) willful fraud, theft or embezzlement
against the Company Group; (C) willful and material failure to perform lawful duties as President and Chief Scientific Officer after a
specific written demand identifying the deficiency and at least thirty (30) days to cure where curable; (D) willful and material breach
of this Agreement or a material written Company policy applicable to senior executives, after thirty (30) days’ written notice and
opportunity to cure where curable; or (E) willful misconduct or gross negligence resulting in demonstrable material harm to the Company
Group. An act is not “willful” if undertaken in good faith with a reasonable belief that it served the Company’s interests.
No termination for Cause shall occur without written particulars and a reasonable opportunity for Executive and counsel to respond to
disinterested Board members. Executive shall recuse himself from the Board’s determination. Cause shall not include mere business
disagreement, an unsuccessful good-faith strategic decision, or failure to meet results in the absence of misconduct. Notwithstanding
the foregoing, no Cause shall exist unless the Company has provided the Executive written notice detailing the event constituting Cause
and, to the extent the event is reasonably susceptible to cure, the Executive does not cure such event within thirty (30) days of the
receipt of such notice.
(v) “Good Reason” means,
without Executive’s prior written consent: (A) any reduction in Base Salary (except for a decrease of not more than ten percent
(10%) in connection with any across-the-board reduction impacting substantially all executives of the Company); (B) a material decrease
in the target Annual Bonus opportunity; (C) material diminution of Executive’s responsibilities, authority or status as President
and Chief Scientific Officer; (D) required relocation of Executive’s principal work location by more than twenty-five (25) miles;
(E) material breach of this Agreement by the Company, including repeated failure to pay amounts when due; or (F) failure of a successor
to assume this Agreement. Executive shall notify the Company within ninety (90) days after learning of the condition, the Company shall
have thirty (30) days to cure, and Executive shall terminate within ninety (90) days following expiration of the cure period if uncured.”
4
7. Resignations. Section 5(g) of the Agreement
is amended and restated in its entirety to read as follows:
“(g) Officer/Board/Committee
Resignations. Upon termination of employment, Executive shall resign from Company officer positions, but a resignation from the Board
shall be subject to applicable law, the Company’s governing documents and any separately negotiated Board transition arrangement.
No deemed resignation shall deprive Executive of rights arising from a Company-initiated removal that constitutes Good Reason, or of accrued
equity, indemnification or advancement rights.”
8. Cross-References. The references to
“Section 3(c)” in Sections 5(f)(i) and 5(h)(iii) of the Agreement are each replaced with “Section 3(d)”.
9. Consent to Jurisdiction. Section 12
of the Agreement is amended and restated in its entirety to read as follows:
“12. Consent to Jurisdiction.
Subject to mandatory statutory venue and jurisdiction rules, the parties consent to the state and federal courts located in California
for claims arising from this Agreement, and waive objections to personal jurisdiction where lawful. Either party may seek provisional
equitable relief in an otherwise competent court, without waiving available defenses or statutory rights. Service of process shall comply
with applicable law. Nothing herein limits a right to pursue a claim before an administrative agency.”
10. Indemnification. Section 15 of the
Agreement is amended and restated in its entirety to read as follows:
“15. Indemnification. To
the fullest extent permitted by Delaware law and the Company’s governing documents, the Company shall indemnify Executive for actions
taken in good faith in Executive’s capacity as an officer and director of the Company, and shall advance reasonable defense expenses
promptly upon appropriate undertaking where legally required. The Company and Executive shall enter into a separate written indemnification
agreement no less favorable than those of the Company’s other directors and executive officers. The Company shall maintain commercially
reasonable directors’ and officers’ liability insurance covering Executive on terms no less favorable than other senior officers
and directors throughout service and, for claims relating to such service, appropriate run-off/tail coverage for at least six (6) years
following a Change in Control, subject to commercially reasonable availability and cost. Executive may use independent counsel at Company
expense when an actual material conflict warrants it, to the extent legally permitted. These obligations survive termination.”
11. Entire Agreement; Amendment. Section
16 of the Agreement is amended and restated in its entirety to read as follows:
“16. Entire Agreement; Amendment.
This Agreement (as amended by Amendment No. 1 hereto), the award agreement(s) evidencing any equity awards granted to Executive,
the separate indemnification agreement, any Wage Deferral Agreement and Acknowledgment between the Company and Executive and the completed
Exhibit A hereto embody the entire agreement of the parties hereto respecting the matters within their scope and supersede all prior
agreements, whether written or oral, that directly or indirectly bear upon the subject matter hereof, excluding any restrictive covenant
agreement by and between Executive and any Company Group Member. This Agreement may not be amended, modified or changed (in whole or
in part), except by written agreement executed by Executive and a duly authorized officer of the Company following any required approval
of the Board or the Compensation Committee.”
5
12. Notices. The address of the Company
for notices under Section 19 of the Agreement is amended to read as follows: Estrella Immunopharma, Inc., 5858 Horton Street, Suite 370,
Emeryville, CA 94608, Attention: Chief Financial Officer.
13. Base Salary Deferral. Executive acknowledges
that, in order to preserve the Company’s cash resources pending the completion of additional financing, the Company has deferred
payment of Executive’s Base Salary beginning with the May 22, 2026 pay date, and that Executive has agreed to enter into a Wage
Deferral Agreement and Acknowledgment with the Company documenting such deferral on the terms approved by the Compensation Committee and
the Board. Executive agrees that such deferral, as applied to Base Salary as adjusted by this Amendment, does not constitute a reduction
in Base Salary, a breach of the Agreement by the Company or Good Reason, and that nothing in this Amendment accelerates the payment of
any amount so deferred.
14. Effect of Amendment. Except as expressly
amended by this Amendment, the Agreement remains in full force and effect, and from and after the Amendment Effective Date all references
in the Agreement to the “Agreement” shall mean the Agreement as amended by this Amendment. This Amendment shall be governed
by the law governing the Agreement and may be executed in counterparts, including by electronic signature, each of which shall be deemed
an original and all of which together shall constitute one instrument.
[Signature page follows]
6
IN WITNESS WHEREOF, the parties have executed
this Amendment No. 1 to Employment Agreement as of the Amendment Effective Date.
COMPANY:
EXECUTIVE:
Estrella Immunopharma, Inc.
By:
/s/ Peter Xu
/s/ Cheng Liu
Name:
Peter Xu
Cheng Liu
Title:
Chief Financial Officer
Date:
October 25, 2026
Date: October 25, 2026
[Signature Page to Amendment No. 1 to Employment
Agreement]
7
EX-10.3 — AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND JIANDONG (PETER) XU
EX-10.3
Filename: ea031020901ex10-3.htm · Sequence: 4
Exhibit 10.3
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT
This Amendment No. 1 to Employment Agreement (this
“Amendment”) is made and entered into effective as of October 25, 2026 (the “Amendment Effective Date”), by and
between Estrella Immunopharma, Inc., a Delaware corporation (the “Company”), and Jiandong (Peter) Xu (“Executive”).
Capitalized terms used but not defined in this Amendment have the meanings given to them in the Agreement (as defined below).
WHEREAS, the Company and Executive are parties
to that certain Employment Agreement dated as of September 29, 2023 (the “Agreement”); and
WHEREAS, the Company and Executive desire to amend
the Agreement as set forth herein, and the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”)
and the Board of Directors of the Company (the “Board”) have approved this Amendment.
NOW, THEREFORE, in consideration of the mutual
covenants herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
agree as follows:
1. Compensation. Sections 3(a), 3(b), 3(d)
and 3(e) of the Agreement are amended and restated in their entirety to read as follows, and Section 3(c) of the Agreement is unchanged:
“(a) Base Salary. Executive’s
current annual Base Salary is US$250,000, payable on the Company’s normal payroll schedule. Base Salary shall increase automatically,
without further Board or Compensation Committee action, to $400,000 when Cumulative Qualifying Funding first exceeds $35,000,000; to $450,000
when it first exceeds $55,000,000; and to $525,000 when it first exceeds $75,000,000. “Cumulative Qualifying Funding” means
the aggregate cash actually received by the Company or its controlled subsidiaries on or after the Amendment Effective Date (as defined
in Amendment No. 1 to this Agreement) through equity investments (including PIPEs), strategic investments, grants, licensing or partnership
upfront payments and milestone payments, acquisition-related net cash proceeds, acquired unrestricted cash that becomes available to the
Company, and other business-development financing transactions. Amounts shall count once only, net of amounts returned, refunded or cancelled;
announced deal values, contingent unpaid consideration and undrawn credit facilities do not count until received. Separate tranches count
when received; multiple qualifying transactions aggregate. The increased Base Salary becomes effective on the date the applicable threshold
is exceeded and any retroactive payroll difference shall be paid in the next practicable payroll, no later than 30 days thereafter. Once
attained, any Base Salary level is permanent and shall never be reduced, including as part of an across-the-board reduction, due to later
expenditures or declines in cash balance, or otherwise, without Executive’s express written consent. The Board may increase but
shall not decrease Base Salary. The Company shall maintain and provide Executive on reasonable request an accounting of qualifying receipts.
The parties acknowledge that a portion of Base Salary constitutes consideration for the enforceable covenants under Section 6.
(b) Annual Cash Bonus. Executive
shall have an annual target cash bonus opportunity (the “Annual Bonus”) equal to sixty percent (60%) of Base Salary for the
fiscal year ending December 31, 2026 and thereafter no less than fifty-five percent (55%) and up to seventy percent (70%) of Base Salary,
with the annual target percentage established in writing by the Compensation Committee of the Board (the “Compensation Committee”)
no later than 60 days after the start of each fiscal year; absent timely written adjustment, the target shall remain 60%, and no decrease
below a prior approved higher target may occur without Executive’s written consent. The Compensation Committee shall establish objective,
reasonably achievable financial, clinical, operational, strategic-transaction and individual performance objectives after consultation
with Executive. Achievement above target may merit payment above target pursuant to an approved bonus program. Bonuses shall be calculated
using Base Salary actually earned during the fiscal year, accounting for salary accelerators, and shall be paid no later than March 15
of the following year, subject to legally required deferral provisions. On a termination without Cause or resignation for Good Reason,
Executive shall receive a prorated target Annual Bonus for the termination year, payable under Section 5(c). Any Annual Bonus for a completed
performance year shall remain payable notwithstanding separation before the ordinary payment date, except termination for Cause.
(d) Reimbursement of Business
Expenses. The Company shall reimburse reasonable, documented expenses incurred for Company business, including air and ground travel,
appropriate lodging, communications, professional memberships, investor/partner meetings, and reasonable meals and entertainment. Executive
may book reasonable executive-level accommodations consistent with Company resources and business needs. No relocation shall be required.
Reimbursement shall be made within 30 days after submission of documentation (or earlier when required by law); advance approval rules
must be reasonable, disclosed in writing and not applied retroactively.
(e) Clawback Policy. To the extent
required by applicable law or regulation, any applicable stock exchange listing standards or any clawback policy adopted by the Company
pursuant to any such law, regulation or stock exchange listing standards (including, without limitation, the Company’s compensation
recovery policy adopted pursuant to Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule
10D-1 thereunder and Nasdaq Listing Rule 5608, as in effect from time to time), or to comport with good corporate governance practices,
the Annual Bonus and any other incentive compensation granted to Executive (whether pursuant to this Employment Agreement or otherwise)
shall be subject to the provisions of any applicable clawback policies or procedures, which may provide for forfeiture and/or recoupment
of such amounts paid or payable under this Employment Agreement or otherwise, including incentive equity awards granted to Executive.”
2. Employee Benefits. Section 4(a) of the
Agreement is amended and restated in its entirety to read as follows:
“(a) Company Employee Benefit
Plans. During the Period of Employment, Executive and Executive’s eligible dependents shall be eligible to participate in all health,
dental, vision, life, disability and retirement programs available to similarly situated executives of the Company, subject to applicable
plan terms, and to receive benefits no less favorable than those afforded to other senior officers of the Company. The Company may modify
generally applicable plans in compliance with law, but shall not selectively reduce Executive’s contractual compensation or negotiated
rights. The Company shall provide a current written summary of available coverage, premium sharing and eligibility upon Executive’s
request.”
2
3. Severance. Sections 5(c)(ii), 5(c)(iii)
and 5(c)(iv) of the Agreement are amended and restated in their entirety to read as follows, and Section 5(c)(v) of the Agreement is deleted:
“(ii) If, during the Period
of Employment, Executive’s employment with the Company ends as a result of an involuntary termination by the Company without Cause
or Executive’s resignation for Good Reason other than in connection with a Change in Control, then, in addition to the amounts payable
under Section 5(c)(i), subject to Executive’s timely execution and non-revocation of the general release described in Section 5(d)
(the “General Release”) and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve
(12) months of Base Salary (at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good
Reason triggered by a reduction in Base Salary, the rate in effect prior to the reduction), payable in substantially equal installments
on each of the Company’s regular payroll payment dates during the twelve (12) months following the Separation Date; (B) to the extent
unpaid as of the Separation Date, the Annual Bonus for the fiscal year immediately preceding the year in which the Separation Date occurs,
payable at the time such Annual Bonus would otherwise have been paid under Section 3(b); (C) a prorated target Annual Bonus for the fiscal
year in which the Separation Date occurs, payable in a lump sum on the first regular payroll date following the effectiveness of the General
Release; and (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums
for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon
Executive’s eligibility for substantially comparable employer-sponsored coverage ((A) through (D) collectively, the “Severance
Payments”); provided, that no installment or portion of the Severance Payments shall be payable or paid until the expiration of
the applicable revocation period for the General Release. Notwithstanding anything herein to the contrary, if any Severance Payment is
“nonqualified deferred compensation” within the meaning of Section 409A and the period to consider and, if applicable, revoke
the General Release plus the first regular payroll date thereafter spans two calendar years, then no portion of the Severance Payments
shall be paid until the Company’s first payroll payment date in the second calendar year, and any amount not paid prior to such
date due to such restriction shall be paid in a lump sum along with the installment scheduled to be paid on that date.
(iii) If Executive’s employment
is terminated by the Company without Cause or by Executive for Good Reason within the ninety (90) days prior to a Change in Control or
within the twelve (12) months following a Change in Control, then, in addition to the amounts payable under Section 5(c)(i) but in lieu
of the Severance Payments payable under Section 5(c)(ii), subject to Executive’s timely execution and non-revocation of the General
Release and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve (12) months of Base Salary
(at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good Reason triggered by a reduction
in Base Salary, the rate in effect prior to the reduction), payable in a lump sum on the first regular payroll date following the effectiveness
of the General Release; (B) to the extent unpaid as of the Separation Date, the Annual Bonus for the fiscal year immediately preceding
the year in which the Separation Date occurs, payable at the time such Annual Bonus would otherwise have been paid under Section 3(b);
(C) a lump-sum payment, payable on the first regular payroll date following the effectiveness of the General Release, equal to one hundred
percent (100%) of Executive’s target Annual Bonus for the fiscal year in which the Separation Date occurs (which amount shall not
be prorated); (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums
for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon
Executive’s eligibility for substantially comparable employer-sponsored coverage; and (E) acceleration of one hundred percent (100%)
of Executive’s outstanding unvested equity awards as of the Separation Date; provided, however, that if an outstanding equity award
is to vest and/or the amount of the equity award to vest is to be determined based on the achievement of performance criteria, then the
equity award will vest as to one hundred percent (100%) of the amount of the equity award assuming the performance criteria had been achieved
at target levels for the relevant performance period(s), unless otherwise provided in the applicable award agreement ((A) through (E)
collectively, the “Change in Control Severance Payments”). For a qualifying termination occurring prior to a Change in Control,
any equity award that was forfeited on the Separation Date shall be treated as having remained outstanding through the closing of the
Change in Control for purposes of this clause (E), to the extent permitted by the applicable plan.
3
(iv) A material, finally determined
breach by Executive of enforceable continuing obligations under Section 6, after written notice and a reasonable opportunity to cure where
curable, may permit only prospective suspension of amounts not legally protected, subject to applicable law and judicial review. Accrued
wages, earned bonuses, vested equity and indemnification rights shall not be forfeited solely by allegation of breach.”
4. Exclusive Remedy. Section 5(e) of the
Agreement is amended and restated in its entirety to read as follows:
“(e) Exclusive Remedy.
Section 5(c) provides the parties’ agreed contractual severance treatment but shall not preclude Executive from enforcing this Agreement,
exercising vested equity rights, recovering accrued salary or earned bonuses, asserting indemnification or advancement rights, seeking
relief for discrimination, retaliation or other statutory violations, or pursuing benefits expressly protected by applicable law. Nothing
herein requires waiver of claims that cannot legally be waived.”
5. Certain Defined Terms. Sections 5(f)(ii)
and 5(f)(v) of the Agreement are amended and restated in their entirety to read as follows:
“(ii) “Cause”
means (A) final conviction of or guilty/nolo contendere plea to a felony involving dishonesty or material harm to the Company or its affiliates
or subsidiaries (the “Company Group” and each a “Company Group Member”); (B) willful fraud, theft or embezzlement
against the Company Group; (C) willful and material failure to perform lawful duties as Chief Financial Officer after a specific written
demand identifying the deficiency and at least thirty (30) days to cure where curable; (D) willful and material breach of this Agreement
or a material written Company policy applicable to senior executives, after thirty (30) days’ written notice and opportunity to
cure where curable; or (E) willful misconduct or gross negligence resulting in demonstrable material harm to the Company Group. An act
is not “willful” if undertaken in good faith with a reasonable belief that it served the Company’s interests. No termination
for Cause shall occur without written particulars and a reasonable opportunity for Executive and counsel to respond to disinterested Board
members. If Executive is then a member of the Board, Executive shall recuse himself from the Board’s determination. Cause shall
not include mere business disagreement, an unsuccessful good-faith strategic decision, or failure to meet results in the absence of misconduct.
Notwithstanding the foregoing, no Cause shall exist unless the Company has provided the Executive written notice detailing the event constituting
Cause and, to the extent the event is reasonably susceptible to cure, the Executive does not cure such event within thirty (30) days of
the receipt of such notice.
4
(v) “Good Reason” means,
without Executive’s prior written consent: (A) any reduction in Base Salary (except for a decrease of not more than ten percent
(10%) in connection with any across-the-board reduction impacting substantially all executives of the Company); (B) a material decrease
in the target Annual Bonus opportunity; (C) material diminution of Executive’s responsibilities, authority or status as Chief Financial
Officer; (D) required relocation of Executive’s principal work location by more than twenty-five (25) miles; (E) material breach
of this Agreement by the Company, including repeated failure to pay amounts when due; or (F) failure of a successor to assume this Agreement.
Executive shall notify the Company within ninety (90) days after learning of the condition, the Company shall have thirty (30) days to
cure, and Executive shall terminate within ninety (90) days following expiration of the cure period if uncured.”
6. Resignations. Section 5(g) of the Agreement
is amended and restated in its entirety to read as follows:
“(g) Officer/Board/Committee
Resignations. Upon termination of employment, Executive shall resign from all officer positions with the Company Group and from any position
as a fiduciary of any employee benefit plan of the Company Group. No deemed resignation shall deprive Executive of rights arising from
a Company-initiated removal that constitutes Good Reason, or of accrued equity, indemnification or advancement rights.”
7. Cross-References. The references to
“Section 3(c)” in Sections 5(f)(i) and 5(h)(iii) of the Agreement are each replaced with “Section 3(d)”.
8. Consent to Jurisdiction. Section 11
of the Agreement is amended and restated in its entirety to read as follows:
“11. Consent to Jurisdiction.
Subject to mandatory statutory venue and jurisdiction rules, the parties consent to the state and federal courts located in California
for claims arising from this Agreement, and waive objections to personal jurisdiction where lawful. Either party may seek provisional
equitable relief in an otherwise competent court, without waiving available defenses or statutory rights. Service of process shall comply
with applicable law. Nothing herein limits a right to pursue a claim before an administrative agency.”
9. Indemnification. Section 14 of the Agreement
is amended and restated in its entirety to read as follows:
“14. Indemnification. To
the fullest extent permitted by Delaware law and the Company’s governing documents, the Company shall indemnify Executive for actions
taken in good faith in Executive’s capacity as an officer of the Company, and shall advance reasonable defense expenses promptly
upon appropriate undertaking where legally required. The Company and Executive shall enter into a separate written indemnification agreement
no less favorable than those of the Company’s other directors and executive officers. The Company shall maintain commercially reasonable
directors’ and officers’ liability insurance covering Executive on terms no less favorable than other senior officers and
directors throughout service and, for claims relating to such service, appropriate run-off/tail coverage for at least six (6) years following
a Change in Control, subject to commercially reasonable availability and cost. Executive may use independent counsel at Company expense
when an actual material conflict warrants it, to the extent legally permitted. These obligations survive termination.”
5
10. Entire Agreement; Amendment. Section
15 of the Agreement is amended and restated in its entirety to read as follows:
“15. Entire Agreement; Amendment.
This Agreement (as amended by Amendment No. 1 hereto), the award agreement(s) evidencing any equity awards granted to Executive,
the separate indemnification agreement, any Wage Deferral Agreement and Acknowledgment between the Company and Executive and the completed
Exhibit A hereto embody the entire agreement of the parties hereto respecting the matters within their scope and supersede all prior
agreements, whether written or oral, that directly or indirectly bear upon the subject matter hereof, excluding any restrictive covenant
agreement by and between Executive and any Company Group Member. This Agreement may not be amended, modified or changed (in whole or
in part), except by written agreement executed by Executive and a duly authorized officer of the Company following any required approval
of the Board or the Compensation Committee.”
11. Notices. The address of the Company
for notices under Section 18 of the Agreement is amended to read as follows: Estrella Immunopharma, Inc., 5858 Horton Street, Suite 370,
Emeryville, CA 94608, Attention: Chief Executive Officer.
12. Base Salary Deferral. Executive acknowledges
that, in order to preserve the Company’s cash resources pending the completion of additional financing, the Company has deferred
payment of Executive’s Base Salary beginning with the May 22, 2026 pay date, and that Executive has agreed to enter into a Wage
Deferral Agreement and Acknowledgment with the Company documenting such deferral on the terms approved by the Compensation Committee and
the Board. Executive agrees that such deferral, as applied to Base Salary as adjusted by this Amendment, does not constitute a reduction
in Base Salary, a breach of the Agreement by the Company or Good Reason, and that nothing in this Amendment accelerates the payment of
any amount so deferred.
13. Effect of Amendment. Except as expressly
amended by this Amendment, the Agreement remains in full force and effect, and from and after the Amendment Effective Date all references
in the Agreement to the “Agreement” shall mean the Agreement as amended by this Amendment. This Amendment shall be governed
by the law governing the Agreement and may be executed in counterparts, including by electronic signature, each of which shall be deemed
an original and all of which together shall constitute one instrument.
[Signature page follows]
6
IN WITNESS WHEREOF, the parties have executed
this Amendment No. 1 to Employment Agreement as of the Amendment Effective Date.
EXECUTIVE:
COMPANY:
Estrella Immunopharma, Inc.
By:
/s/ Cheng Liu
/s/ Jiandong (Peter) Xu
Name:
Cheng Liu
Jiandong (Peter) Xu
Title:
President and Chief Scientific Officer
Date: October 25, 2026
Date: October 25, 2026
[Signature Page to Amendment No. 1 to Employment
Agreement]
7
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 10
v3.26.3
Cover
Oct. 25, 2026
Document Type
8-K
Amendment Flag
false
Document Period End Date
Oct. 25, 2026
Entity File Number
001-40608
Entity Registrant Name
ESTRELLA IMMUNOPHARMA, INC.
Entity Central Index Key
0001844417
Entity Tax Identification Number
86-1314502
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
5858 Horton Street
Entity Address, Address Line Two
Suite 370
Entity Address, City or Town
Emeryville
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
94608
City Area Code
510
Local Phone Number
318-9098
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
false
Common Stock, par value $0.0001 per share
Title of 12(b) Security
Common Stock, par value $0.0001 per share
Trading Symbol
ESLA
Security Exchange Name
NASDAQ
Warrants, each warrant exercisable for one share of Common Stock, each at an exercise price of $11.50 per share
Title of 12(b) Security
Warrants, each warrant exercisable for one share of Common Stock, each at an exercise price of $11.50 per share
Trading Symbol
ESLAW
Security Exchange Name
NASDAQ
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=ESLA_CommonStockParValue0.0001PerShareMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=ESLA_WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: